Guided_by_Voices
Well-Known Member
FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women
PT-141 AKA Bremelanotide AKA Vyleesi approved. This should open up a whole new focus on the melanocortin system and allow for crowdsourcing the best dosing/timing. It seems something good is happening in regards to forward-thinking treatments in general given the expansion of available peptides and other new options.
PT-141 AKA Bremelanotide AKA Vyleesi approved. This should open up a whole new focus on the melanocortin system and allow for crowdsourcing the best dosing/timing. It seems something good is happening in regards to forward-thinking treatments in general given the expansion of available peptides and other new options.
Last edited:
